Drug intelligence / Profile preview

MG-5-325

Development stage: Unknown
Lead developer: Metagone Biotech
Modality: Small Molecules

Overview

MG-5-325 is a small molecule inhibitor of Mitogen-activated protein kinase 3 (MAPK3), also known as ERK1, currently under development by Metagone Biotech. It is primarily being investigated for the treatment of acute pharyngeal inflammation (API). MAPK3 is a key component of the extracellular signal-regulated kinase (ERK) signaling pathway, which regulates various cellular processes including the production of pro-inflammatory cytokines. By targeting MAPK3, MG-5-325 aims to modulate the inflammatory response in the pharyngeal mucosa, providing a therapeutic approach for acute upper respiratory inflammatory conditions. The drug is currently in Phase 2 clinical development.

Targets

MAPK3 (Mitogen-activated protein kinase 1)

Beyond the preview

Go deeper on MG-5-325.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MG-5-325.

Explore the full profile